Differential antinociceptive effects of buprenorphine and methadone in the presence of HIV-gp120

作者：Palma Jonathan; Cowan Alan; Geller Ellen B; Adler Martin W; Benamar Khalid^*

来源：Drug and Alcohol Dependence, 2011, 118(2-3): 497-499.

DOI：10.1016/j.drugalcdep.2011.04.010

• Buprenorphine
• HIV
• Gp120
• Antinociception
• PAG
• Chemokine

Background: We showed recently that elevated brain levels of the chemokine stromal cell-derived growth factor-1 alpha (SDF-1 alpha/CXCL12, a ligand for the human immunodeficiency virus [HIV] co-receptor CXCR4) diminish the antinociceptive effect of morphine, but failed to influence buprenorphine-induced antinociception.
Aims: Because the HIV-1 coat protein, glycoprotein 120 (gp120)T-tropic strain, binds to the same receptor as SDF-1 alpha/CXCL12, the present experiments were designed to investigate the consequence of administering gp120 to rat brain on buprenorphine-induced antinociception in the 54 degrees C hot plate test. For comparative purposes, the effect of gp120 on an equi-antinociceptive dose of methadone was also examined.
Methods: A sterilized stainless-steel C313G guide cannula was implanted into the periaqueductal grey (PAG), a brain region critical for the processing of pain signals, and a primary site of action of many analgesics. Rats were pretreated with gp120, administered into the PAG.
Results: The subsequent antinociception associated with methadone was diminished whereas buprenorphine-induced antinociception was unaffected. Buprenorphine thus appears to be a more effective analgesic than methadone in the presence of gp120 in the brain, a condition that is associated with HIV-related pain and infection. Published by Elsevier Ireland Ltd.

• 出版日期2011-11-1